Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-free survival (RFS) of 99.6%

Separate ePoster shows DecisionDx-Melanoma identifies early-stage, transected melanomas with recurrence risk similar to that seen in stage IIB disease, supporting closer surveillance when staging is uncertain

FRIENDSWOOD, Texas, Sept. 30, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on DecisionDx-Melanoma at the European Academy of Dermatology and Venereology (EADV) Congress 2026, taking place Sept. 30–Oct. 3 in Vienna, Austria.

A late-breaking oral presentation will highlight the largest prospective, multi-center study of gene expression profiling (GEP) in cutaneous melanoma to date, involving 2,799 patients across 29 U.S. centers. The findings support using DecisionDx-Melanoma to identify patients who may safely forgo SLNB and patients with early-stage disease whose higher recurrence risk may warrant closer surveillance.